Azurity Pharmaceuticals Absorbs Slayback Pharma
September 29, 2023
Source: drugdu
176
The company expects to yield a significant number of new medicine launches from the acquisition.
Azurity Pharmaceuticals, Inc. broke the news that it has officially acquired Slayback Pharma LLC from existing investors including KKR and Everstone Capital, making it a wholly owned subsidiary. According to Azurity, the acquisition is expected to realize its purpose of serving overlooked patients, hoping to yield a significant number of new medicine launches over the coming years.
"I am delighted to announce this combination and the increased potential it brings to do more for overlooked patients," said Richard Blackburn, CEO, Azurity. "The complementary expertise of the two companies in developing innovative dose forms will result in a strong pipeline of new medicines to meet the needs of patients. We will bring the commercial expertise of Azurity to Slayback's pipeline and look forward to introducing an even wider range of dose-forms and formulations to meet a broader set of patient needs."
Copyright©2024 Ddu. All rights reserved.
Read more on
- Tirzepatide’s new indication is approved by the FDA, becoming the first drug to treat “snoring” December 28, 2024
- Another senior executive of Baiyunshan was taken away within half a year December 28, 2024
- FDA approves first “off-the-shelf” mesenchymal cell therapy December 28, 2024
- Longsha Capsules and Health Ingredients Expand Capsule Production Capacity in China and India December 28, 2024
- 744 million! Medical equipment dark horse completes Series C financing again December 28, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
